FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease


You May Also Like

Incysus Scientific Co-Founder to Present at Immuno-Oncology Summit

HAMILTON, Bermuda, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd, a biopharmaceutical company focused ...

Tyme Announces Prostate Cancer Collaboration with Dr. Mack Roach III of UCSF

NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage ...